Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial–mesenchymal transition

This study aimed to investigate the role of ANXA13 in lung adenocarcinoma (LUAD) growth, migration, and the underlying mechanisms. Firstly, in the TCGA dataset for LUAD, ANXA13 is found to be highly expressed in patients with LUAD and high expression of ANXA13 predicted poor outcomes in LUAD patients. Consistently, the data of qRT‐PCR showed that the expression of ANXA13 was higher in LUAD cell lines (Calu‐3, LTEP‐a‐2, and NCI‐H1395) than that in normal lung cell line BEAS2B. Then, we performed gain‐ and loss of function of ANXA13 in NCI‐H1395 and Calu‐3 cells, respectively. The results displayed that deficiency of ANXA13 suppresses cell proliferation, invasion, and migration in Calu‐3 cells and overexpression of ANXA13 augments cell proliferation, invasion, and migration in NCI‐H1395 cells. Finally, it was found that silencing of ANXA13 obviously raised the protein expression levels of E‐cadherin and reduced the protein levels of N‐cadherin, Vimentin, and Snail in Calu‐3 cells whereas overexpression of ANXA13 obviously receded the protein expression levels of E‐cadherin and enhanced the protein levels of N‐cadherin, Vimentin, and Snail in NCI‐H1395 cells. This study analyzed the biological effects of ANXA13 in LUAD cells, indicating that ANXA13 could regard as a therapeutic target for LUAD.